GPCR Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

-0.377

+71.36%

-0.378

+39.9%

-0.399

+10.96%

Estimates Revision

The market is revising Downward the revenue expectations for Structure Therapeutics Inc. (GPCR) for FY2025, with the revenue forecasts being adjusted by -96.45% over the past three months. During the same period, the stock price has changed by 119.25%.

Revenue Estimates for FY2025

Revise Downward

-96.45%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.44%

In Past 3 Month

Stock Price

Go Up

+119.25%

In Past 3 Month

10 Analyst Rating

Wall Street analysts forecast GPCR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GPCR is 74.00 USD with a low forecast of 50.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

50.00

Averages

74.00

High

100.00

Current: 0.000

Low

50.00

Averages

74.00

High

100.00

H.C. Wainwright

Ananda Ghosh

Buy

upgrade

$60 -> $90

2025-12-19

Reason

H.C. Wainwright

Ananda Ghosh

Price Target

$60 -> $90

2025-12-19

upgrade

Buy

Reason

H.C. Wainwright analyst Ananda Ghosh raised the firm's price target on Structure Therapeutics to $90 from $60 and keeps a Buy rating on the shares. The firm says its key opinion leader feedback validates the company's titration strategy. With oral GLP-1s set to become "Tier 1 therapies" driven by payer economics, Structure's current valuation offers a "massive arbitrage opportunity relative to recent deal metrics with a strong M&A potential," the analyst tells investors in a research note. H.C. Wainwright views the company's recent Phase 2 data as encouraging.

Citi

Samantha Semenkow

Buy

maintain

$60 -> $100

2025-12-09

Reason

Citi

Samantha Semenkow

Price Target

$60 -> $100

2025-12-09

maintain

Buy

Reason

Citi analyst Samantha Semenkow raised the firm's price target on Structure Therapeutics to $100 from $60 and keeps a Buy rating on the shares. The positive Phase 2b data for aleniglipron gives Structure an attractive oral obesity asset, the analyst tells investors in a research note. The firm sees the drug getting "significant interest from strategics" looking to enter the oral obesity market. Citi believes aleniglipron showed "potential best-in-class" weight loss with competitive tolerability.

Morgan Stanley

Terence Flynn

Overweight

maintain

$120

2025-12-08

Reason

Morgan Stanley

Terence Flynn

Price Target

$120

2025-12-08

maintain

Overweight

Reason

After Structure Therapeutics (GPCR) announced topline data from the ACCESS clinical program of aleniglipron for the treatment of people living with obesity and/or overweight with at least one weight related co-morbidity, Morgan Stanley analyst Terence Flynn argues that 36-week data from the core Phase 2b ACCESS study "appear competitive" with Eli Lilly's (LLY) orforglipron. The firm, which models an aleniglipron U.S. launch in 2028 and 2040 worldwide unadjusted sales of $6.3B, has an Overweight rating and $120 price target on Structure shares.

H.C. Wainwright

maintain

$60

2025-12-08

Reason

H.C. Wainwright

Price Target

$60

2025-12-08

maintain

Reason

After Structure Therapeutics (GPCR) released pivotal topline data from the Phase 2b ACCESS program, H.C. Wainwright argues that the clean safety profile along with 15.3% placebo-adjusted weight loss at the 240 mg dose shatters the "oral ceiling," exceeding the roughly 12.4% efficacy benchmark set by Eli Lilly's (LLY) orforglipron. The firm, which sees the data validating the "bull case" thesis the firm previously outlined, has a Buy rating and $60 price target on Structure shares.

Stifel

NULL -> Buy

maintain

$50 -> $90

2025-12-08

Reason

Stifel

Price Target

$50 -> $90

2025-12-08

maintain

NULL -> Buy

Reason

Stifel raised the firm's price target on Structure Therapeutics to $90 from $50 and keeps a Buy rating on the shares after both of the ACCESS and ACCESS-II trials confirmed aleniglipron's dose-dependent potency and importantly improved safety profile. Structure "now has a viable and versatile small-molecule offering for independent development or future partnership," the analyst tells investors.

Clear Street

NULL -> Buy

upgrade

$61 -> $99

2025-12-08

Reason

Clear Street

Price Target

$61 -> $99

2025-12-08

upgrade

NULL -> Buy

Reason

Clear Street raised the firm's price target on Structure Therapeutics (GPCR) to $99 from $61 and keeps a Buy rating on the shares. The Phase 2b Access 36-week data underscore aleniglipron's best-in-class potential, delivering up to 15.3% placebo-adjusted weight loss and surpassing the 11.5% benchmark set by Lilly's ( LLY) orforglipron in Phase 3 Attain-1, semaglutide's Phase 3 STEP 1 (36 weeks), and RYBELSUS (oral semaglutide) Phase 2 results (36 weeks), . the analyst tells investors in a research note. The drug's safety profile also remains competitive, with adverse effect-related treatment discontinuations in Access at 10.4% - comparable to Attain-1's 10.3% at Week 72, the firm added.

Valuation Metrics

The current forward P/E ratio for Structure Therapeutics Inc (GPCR.O) is -43.34, compared to its 5-year average forward P/E of -34.32. For a more detailed relative valuation and DCF analysis to assess Structure Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-34.32

Current PE

-43.34

Overvalued PE

-20.42

Undervalued PE

-48.22

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.96

Current EV/EBITDA

-11.92

Overvalued EV/EBITDA

0.19

Undervalued EV/EBITDA

-8.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

4.95

Current PS

0.00

Overvalued PS

14.95

Undervalued PS

-5.06

Financials

Annual

Quarterly

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

GPCR News & Events

Events Timeline

No data

News

7.5

2025-12-31Benzinga

Biotech Stocks Surge at Year-End 2025, ETFs Gain 35.84%

8.5

2025-12-11Newsfilter

Structure Therapeutics Closes $747.5 Million Upsized Public Offering

8.5

2025-12-10Newsfilter

Structure Therapeutics Prices $650 Million Upsized Public Offering

People Also Watch

Frequently Asked Questions

What is Structure Therapeutics Inc (GPCR) stock price today?

The current price of GPCR is 66.98 USD — it has increased 1.1 % in the last trading day.

What is Structure Therapeutics Inc (GPCR)'s business?

Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.

What is the price predicton of GPCR Stock?

What is Structure Therapeutics Inc (GPCR)'s revenue for the last quarter?

Structure Therapeutics Inc revenue for the last quarter amounts to -73.79M USD, increased 60.98 % YoY.

What is Structure Therapeutics Inc (GPCR)'s earnings per share (EPS) for the last quarter?

Structure Therapeutics Inc. EPS for the last quarter amounts to -52568000.00 USD, increased 157.93 % YoY.

What changes have occurred in the market's expectations for Structure Therapeutics Inc (GPCR)'s fundamentals?

How many employees does Structure Therapeutics Inc (GPCR). have?

Structure Therapeutics Inc (GPCR) has 163 emplpoyees as of January 09 2026.

What is Structure Therapeutics Inc (GPCR) market cap?

Today GPCR has the market capitalization of 4.63B USD.